Amgen Inc. (AMGN)
After hours:
| Previous Close | 273.94 |
| Open | 273.55 |
| Bid | 263.87 x 100 |
| Ask | 277.44 x 200 |
| Day's Range | 273.38 - 279.78 |
| 52 Week Range | 211.71 - 329.72 |
| Volume | |
| Avg. Volume | 2,926,600 |
| Market Cap | 148.775B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 22.19 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 9.00 (3.28%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | N/A |
- Reuters
Amgen investors await weight-loss drug data
(Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.
- Zacks
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
- Reuters
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars. The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement. "The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.
